FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082574239> ?p ?o ?g. }

• W2082574239 endingPage "257" @default.
• W2082574239 startingPage "249" @default.
• W2082574239 abstract "Previous studies have established the importance of substitutions at amino acids 36-45 of HIV-1 gp41 in the development of viral resistance to the peptide fusion inhibitor enfuvirtide. However, the influence of other loci in the HIV-1 envelope is not well established.To identify positions showing genotypic changes that are associated with particularly high levels of changes in enfuvirtide susceptibility.We examined full-length baseline and on treatment sequences of gp120 and gp41 for isolates from 369 patients in Phase III studies of enfuvirtide, including 281 patients receiving ENF+OB and 88 patients receiving OB alone. Individual changes in gp41 and gp120 were evaluated for correlations with on treatment phenotype changes by analysis of variance (ANOVA). This modeling was done with (two-way) and without (one-way) ANOVA adjusting for the effects of any changes in gp41 amino acids 36-45 modeled as a single variable (ANY(36-45)). Positions displaying significance levels of p<0.05 by either one- or two-way ANOVA were then studied by multi-way ANOVA (stepwise regression).In addition to changes at gp41 amino acids 36-45, changes at three positions in the HR2 domain (126, 129 and 133) occurred significantly more often in patients undergoing virologic failure on enfuvirtide. However, ANY(36-45) alone accounted for slightly more than 90% of the variation in phenotype explained by the ANOVA models. Relative to ANY(36-45) alone, significant increases in the geometric mean of the fold-change in inhibitory concentration (19.6-236.3-fold higher) were observed for amino acid changes at positions gp41: 18, 42,126, 247, 256 and 312; gp120: 330, 389 and 424 and significant reductions (18.8-29.7-fold lower) for gp41: 3, 46, 165, 232 and 324.This study represents a statistical approach to highlight positions in HIV envelope that undergo mutations in the presence of enfuvirtide. Several of the identified positions have been implicated in the viral fusion process by other studies. The specific impact of positions 330. Three hundred and eighty-nine and 424 on viral fusion kinetics remains to be studied further by site-directed mutagenesis experiments." @default.
• W2082574239 created "2016-06-24" @default.
• W2082574239 creator A5031035471 @default.
• W2082574239 creator A5035336361 @default.
• W2082574239 creator A5050783027 @default.
• W2082574239 creator A5051348384 @default.
• W2082574239 creator A5082773746 @default.
• W2082574239 date "2006-08-01" @default.
• W2082574239 modified "2023-10-03" @default.
• W2082574239 title "Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro" @default.
• W2082574239 cites W1537640815 @default.
• W2082574239 cites W170446279 @default.
• W2082574239 cites W1783564615 @default.
• W2082574239 cites W1987846451 @default.
• W2082574239 cites W1996532819 @default.
• W2082574239 cites W2010521915 @default.
• W2082574239 cites W2034073194 @default.
• W2082574239 cites W2040506631 @default.
• W2082574239 cites W2048336729 @default.
• W2082574239 cites W2054945703 @default.
• W2082574239 cites W2056949060 @default.
• W2082574239 cites W2060620553 @default.
• W2082574239 cites W2063906252 @default.
• W2082574239 cites W2079161413 @default.
• W2082574239 cites W2085739552 @default.
• W2082574239 cites W2098781795 @default.
• W2082574239 cites W2107672429 @default.
• W2082574239 cites W2113396991 @default.
• W2082574239 cites W2120064320 @default.
• W2082574239 cites W2123797944 @default.
• W2082574239 cites W2124921953 @default.
• W2082574239 cites W2125997506 @default.
• W2082574239 cites W2127153680 @default.
• W2082574239 cites W2128574780 @default.
• W2082574239 cites W2132631551 @default.
• W2082574239 cites W2133649749 @default.
• W2082574239 cites W2146478787 @default.
• W2082574239 cites W2148591835 @default.
• W2082574239 cites W2151871810 @default.
• W2082574239 cites W2153747683 @default.
• W2082574239 cites W2157053750 @default.
• W2082574239 cites W2158873843 @default.
• W2082574239 cites W2160959707 @default.
• W2082574239 cites W2405782540 @default.
• W2082574239 cites W2514130249 @default.
• W2082574239 doi "https://doi.org/10.1016/j.jcv.2006.03.007" @default.
• W2082574239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16765082" @default.
• W2082574239 hasPublicationYear "2006" @default.
• W2082574239 type Work @default.
• W2082574239 sameAs 2082574239 @default.
• W2082574239 citedByCount "27" @default.
• W2082574239 countsByYear W20825742392012 @default.
• W2082574239 countsByYear W20825742392013 @default.
• W2082574239 countsByYear W20825742392016 @default.
• W2082574239 countsByYear W20825742392017 @default.
• W2082574239 countsByYear W20825742392019 @default.
• W2082574239 crossrefType "journal-article" @default.
• W2082574239 hasAuthorship W2082574239A5031035471 @default.
• W2082574239 hasAuthorship W2082574239A5035336361 @default.
• W2082574239 hasAuthorship W2082574239A5050783027 @default.
• W2082574239 hasAuthorship W2082574239A5051348384 @default.
• W2082574239 hasAuthorship W2082574239A5082773746 @default.
• W2082574239 hasConcept C104317684 @default.
• W2082574239 hasConcept C108625454 @default.
• W2082574239 hasConcept C126322002 @default.
• W2082574239 hasConcept C127716648 @default.
• W2082574239 hasConcept C135763542 @default.
• W2082574239 hasConcept C147483822 @default.
• W2082574239 hasConcept C159047783 @default.
• W2082574239 hasConcept C195616568 @default.
• W2082574239 hasConcept C203014093 @default.
• W2082574239 hasConcept C2776258796 @default.
• W2082574239 hasConcept C2778037500 @default.
• W2082574239 hasConcept C515207424 @default.
• W2082574239 hasConcept C54355233 @default.
• W2082574239 hasConcept C71924100 @default.
• W2082574239 hasConcept C86803240 @default.
• W2082574239 hasConcept C98274493 @default.
• W2082574239 hasConcept C99476002 @default.
• W2082574239 hasConceptScore W2082574239C104317684 @default.
• W2082574239 hasConceptScore W2082574239C108625454 @default.
• W2082574239 hasConceptScore W2082574239C126322002 @default.
• W2082574239 hasConceptScore W2082574239C127716648 @default.
• W2082574239 hasConceptScore W2082574239C135763542 @default.
• W2082574239 hasConceptScore W2082574239C147483822 @default.
• W2082574239 hasConceptScore W2082574239C159047783 @default.
• W2082574239 hasConceptScore W2082574239C195616568 @default.
• W2082574239 hasConceptScore W2082574239C203014093 @default.
• W2082574239 hasConceptScore W2082574239C2776258796 @default.
• W2082574239 hasConceptScore W2082574239C2778037500 @default.
• W2082574239 hasConceptScore W2082574239C515207424 @default.
• W2082574239 hasConceptScore W2082574239C54355233 @default.
• W2082574239 hasConceptScore W2082574239C71924100 @default.
• W2082574239 hasConceptScore W2082574239C86803240 @default.
• W2082574239 hasConceptScore W2082574239C98274493 @default.
• W2082574239 hasConceptScore W2082574239C99476002 @default.
• W2082574239 hasIssue "4" @default.
• W2082574239 hasLocation W20825742391 @default.

• next